{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:45:45Z","timestamp":1772721945714,"version":"3.50.1"},"reference-count":35,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2020,2,29]]},"DOI":"10.5582\/bst.2019.01313","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T22:03:48Z","timestamp":1580853828000},"page":"42-47","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes of living donor liver transplantation in patients with a prior history of nonhepatic malignancy"],"prefix":"10.5582","volume":"14","author":[{"given":"Hidekazu","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"Sambommatsu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Ibuki","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Shimata","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Hibi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Niazi S, Schneekloth T, Taner CB. Elderly recipients of liver transplantation: impact of age and psychosocial variables on outcome. Curr Opin Organ Transplant. 2017; 22:588-592.","DOI":"10.1097\/MOT.0000000000000469"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Aduen JF, Sujay B, Dickson RC, Heckman MG, Hewitt WR, Stapelfeldt WH, Steers JL, Harnois DM, Kramer DJ. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc. 2009; 84:973-978.","DOI":"10.1016\/S0025-6196(11)60667-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005; 352:1371-1373.","DOI":"10.1056\/NEJMe058018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013; 119:2300-2308.","DOI":"10.1002\/cncr.28043"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10:1889-1896.","DOI":"10.1111\/j.1600-6143.2010.03181.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008; 14:1428-1436.","DOI":"10.1002\/lt.21475"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chatrath H, Berman K, Vuppalanchi R, Slaven J, Kwo P, Tector AJ, Chalasani N, Ghabril M. <i>De novo<\/i> malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant. 2013; 27:582-590.","DOI":"10.1111\/ctr.12171"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., <i>et al<\/i>. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306:1891-1901.","DOI":"10.1001\/jama.2011.1592"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Oechslin E, Kiowski W, Schneider J, Follath F, Turina M, Gallino A. Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. Ann Oncol. 1996; 7:1059-1063.","DOI":"10.1093\/oxfordjournals.annonc.a010499"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Murray KF, Carithers RL, Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005; 41:1407-1432.","DOI":"10.1002\/hep.20704"},{"key":"11","unstructured":"11. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation. 2012; 94:703-713."},{"key":"12","unstructured":"12. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997; 2:14-17."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc. 2001; 33:1830-1831.","DOI":"10.1016\/S0041-1345(00)02698-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chiu HF, Chung MC, Chung CJ, Yu TM, Shu KH, Wu MJ. Prognosis of kidney transplant recipients with pretransplantation malignancy: a nationwide population-based cohort study in Taiwan. Transplant Proc. 2016; 48:918-920.","DOI":"10.1016\/j.transproceed.2015.11.020"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, Rush D, Cole E. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005; 173:1181-1184.","DOI":"10.1503\/cmaj.051291"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kalble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. EAU guidelines on renal transplantation. Eur Urol. 2005; 47:156-166.","DOI":"10.1016\/j.eururo.2004.02.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Acuna SA, Sutradhar R, Kim SJ, Baxter NN. Solid organ transplantation in patients with preexisting malignancies in remission: a propensity score matched cohort study. Transplantation. 2018; 102:1156-1164.","DOI":"10.1097\/TP.0000000000002178"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisaeter AV, Mjoen G, Pihlstrom HK, Naess H, Holdaas H. Association between pretransplant cancer and survival in kidney transplant recipients. Transplantation. 2017; 101:2599-2605.","DOI":"10.1097\/TP.0000000000001659"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Watschinger B, Budde K, Crespo M, Heemann U, Hilbrands L, Maggiore U, Mariat C, Oberbauer R, Oniscu GC, Peruzzi L, Sorensen SS, Viklicky O, Abramowicz D. Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times. Nephrol Dial Transplant. 2019.","DOI":"10.1093\/ndt\/gfz026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Unterrainer C, Opelz G, Dohler B, Susal C, Collaborative Transplant S. Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and <i>De Novo<\/i> Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival. Transplantation. 2019; 103:581-587.","DOI":"10.1097\/TP.0000000000002459"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Acuna SA, Huang JW, Daly C, Shah PS, Kim SJ, Baxter NN.Outcomes of solid organ transplant recipients with preexisting malignancies in remission: a systematic review and meta-analysis. Transplantation. 2017; 101:471-481.","DOI":"10.1097\/TP.0000000000001192"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer. 1998; 83:1237-1243.","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1237::AID-CNCR25>3.0.CO;2-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Saigal S, Norris S, Srinivasan P, Muiesan P, Rela M, Heaton N, O&apos;Grady J. Successful outcome of orthotopic liver transplantation in patients with preexisting malignant states. Liver Transpl. 2001; 7:11-15.","DOI":"10.1053\/jlts.2001.20788"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Benten D, Sterneck M, Panse J, Rogiers X, Lohse AW. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl. 2008; 14:789-798.","DOI":"10.1002\/lt.21434"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jain A, Fiaz O, Sheikh B, Sharma R, Safadjou S, Kashyap R, Bryan L, Batzold P, Orloff M. Recurrent nonhepatic and <i>de novo<\/i> malignancies after liver transplantation. Transplantation. 2009; 88:706-710.","DOI":"10.1097\/TP.0b013e3181b3918e"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hellstrom V, Lorant T, Dohler B, Tufveson G, Enblad G. High posttransplant cancer incidence in renal transplanted patients with pretransplant cancer. Transplantation. 2017; 101:1295-1302.","DOI":"10.1097\/TP.0000000000001225"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sigurdardottir V, Bjortuft O, Eiskjaer H, Ekmehag B, Gude E, Gustafsson F, Hagerman I, Halme M, Lommi J, Mared L, Riise GC, Simonsen S. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. J Heart Lung Transplant. 2012; 31:1276- 1280.","DOI":"10.1016\/j.healun.2012.09.007"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Brattstrom C, Granath F, Edgren G, Smedby KE, Wilczek HE. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation. 2013; 96:297-305.","DOI":"10.1097\/TP.0b013e31829854b7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Girndt M, Kohler H. Waiting time for patients with history of malignant disease before listing for organ transplantation. Transplantation. 2005; 80:S167-170.","DOI":"10.1097\/01.tp.0000187112.81714.26"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Campistol JM, Cuervas-Mons V, Manito N, <i>et al<\/i>. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando). 2012; 26:261-279.","DOI":"10.1016\/j.trre.2012.07.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Shimada Y, Hamaguchi T, Mizusawa J, <i>et al<\/i>. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2\/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014; 50:2231-2240.","DOI":"10.1016\/j.ejca.2014.05.025"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kusumoto T, Ishiguro M, Nakatani E, <i>et al<\/i>. Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil\/leucovorin as adjuvant chemotherapy for stage III colon cancer. ESMO Open. 2018; 3:e000428.","DOI":"10.1136\/esmoopen-2018-000428"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Yoosabai A, Mehta A, Kang W, Chaiwatcharayut W, Sampaio M, Huang E, Bunnapradist S. Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation. Transplantation. 2015; 99:345-350.","DOI":"10.1097\/TP.0000000000000563"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007; 7:2140-2151.","DOI":"10.1111\/j.1600-6143.2007.01908.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Viecelli AK, Lim WH, Macaskill P, Chapman JR, Craig JC, Clayton P, Cohney S, Carroll R, Wong G. Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer. Transplantation. 2015; 99:2586-2592.","DOI":"10.1097\/TP.0000000000000760"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/1\/14_2019.01313\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T03:37:53Z","timestamp":1584761873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/1\/14_2019.01313\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2019.01313","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]}}}